GQ Bio Therapeutics Teilexit

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

Press releases

Press
Series A Investment GeneQuine
26. January 2021

GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases

Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platformLead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to Phase 1 clinical trialGene therapy program for intervertebral disc degeneration will be acceleratedCompany is expanding with additional site and staff GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for mu
 
Press
12. November 2012
GeneQuine Biotherapeutics Closes Seed Financing with High-Tech Gründerfonds and Innovationsstarter Fonds Hamburg
The Hamburg, Germany-based biotech startup GeneQuine Biotherapeutics today announced the completion of a seven-figure seed financing round. Investors are the German seed funds High-Tech Gründerfonds, Bonn and Innovationsstarter Fonds Hamburg. Funding will be used to perform proof-of-concept studies with the lead product - a gene therapy drug for the treatment of osteoarthritis in horses. GeneQuine Biotherapeutics develops gene therapy for the treatment of osteoarthritis, a degenerative joint d
 

Info & Contact

Address

Harburger Schlossstraße 6-12
21079 Hamburg

In portfolio

12. Oct 2012

Sector

HTGF Manager

 
Jakob Lilienweiss, Investment Manager
Exit